The TSX Venture Exchange has accepted for filing documentation with respect to the arm's-length acquisition of 100 per cent in a privately owned company, Oral Science Inc. (the target).

Cash ($)                      Securities         Consideration
                 
$22.5-million      234,192 common shares                   N/A

* $200,000 has been satisfied through the grant of 12,666 restricted share units (RSUs) to certain employees of the target.

The vendors are entitled to a contingent cash earnout payment, and contingent royalty payments until 2033 based on future sales of one product up to a maximum value of $6-million.

No finder's fee was paid.

For further details, please refer to the company's news releases dated Feb. 9, 2026, and March 2, 2026.